Prostate Cancer Companies in BioPortfolio's Corporate Database - Page: 5
Prostate Cancer company data on BioPortfolio. Our corporate data records list over 50,000 company records. Here you can see the latest Prostate Cancer companies that have been added to our BioPortfolio's life-science corporate directory.
Search For More Prostate Cancer Companies
If you don't find the company you're looking for in the list below, you may wish to search our extensive database for further matches: Search for More Prostate Cancer Companies.
More Information about Prostate Cancer on BioPortfolio
We have published hundreds of Prostate Cancer news stories on BioPortfolio along with dozens of Prostate Cancer Clinical Trials. In addition to the corporate data, news and clinical trials, BioPortfolio also has a large collection of PubMed Articles about Prostate Cancer for you to read.
Showing "prostate" Companies 101 to 125 of 136
Cell Works Inc. is an early-stage biomedical company located in Baltimore, Maryland, basing their initial products on research conducted at The Johns Hopkins University (JHU). Cell Works has exclusively licensed certain cell isolation technology from JHU on a worldwide basis. This technology license currently incorporates one patent, one patent application, and related international patent applica...
Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide), and SOLTAMOX™ (tamoxifen citrate) to the U.S. oncology market. Q...
GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. GPC Biotech is also...
Endocare's mission is to radically improve patients lives through ground breaking core technology. Endocare promotes its cryotherapy technology to urologists for the treatment of prostate cancer and renal tumors, however, we are expanding our focus across a number of surgical markets, including the ablation of tumors in the lung and liver, as well as pain management.
GTx, Inc., headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel hormonal therapeutics for cancer and serious conditions related to men’s health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens. GTx is developing...
Matritech, Inc. develops, manufactures and markets innovative cancer diagnostic products based on its proprietarynuclear matrix protein ("NMP") technology. The nuclear matrix, a three dimensional protein framework within the nucleus of cells, plays a fundamental role in determining cell type by physically organizing the contents of the nucleus, including DNA. The Company has demonstrated that th...
Praecis Pharmaceuticals Incorporated (MA)
PRAECIS PHARMACEUTICALS INCORPORATED is a biotechnology company focused on the discovery and development of pharmaceutical products using its proprietary LEAP™ (Ligand Evolution to Active Pharmaceuticals) technology. LEAP combines the power of biological selection with the advantages of medicinal chemistry in a unique molecular evolution process. PRAECIS employed LEAP in the development of PLENA...
Progen Pharmaceuticals Limited (NASDAQ:PGLA; ASX: PGL) is a globally focused biotechnology company committed to improving patient outcomes through discovery and development of small molecule-based cancer therapeutics. The company has an intimate understanding of the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program i...
Sense Proteomic Limited is a biomarker discovery company utilising its proprietary protein array technology to discover and commercialise autoantibody biomarkers for cancer and autoimmune diseases. We have developed a novel functional protein array technology which allows thousands of human proteins to be analysed in a single experiment. Our primary focus is on using our technology to discover new...
Signet Laboratories Incorporated
Signet Laboratories, Inc is a medical biotechnology company focused in fields of cancer and infectious disease(Sepsis). Signet has developed proprietary antibody systems for the detection and management of breast and prostate cancer and Sepsis. Signet's patented technology will provide for determining risk in "normal patients who may be at increased risk for developing cancer at a time when proac...
Xcyte Therapies, Inc., a Seattle-based biotechnology company, is developing and commercializing novel cell-based or cellular therapeutic products that harness the power of the immune system to treat cancer and many infectious diseases. It was founded in 1996 by Ron Berenson, MD, a biotechnology veteran and founder of CellPro. Xcyte Therapies has an experienced management team with a proven track r...
Agensys, Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers based on its own proprietary targets. The Company has discovered and validated a rich portfolio of novel, clinically relevant cancer targets to 14 different cancer types that have been carefully selected to enable development of new effective therapeutics with fewer and less...
AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in medicine. AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease an...
provides services and biological human materials to biotech and pharmaceutical companies to support their basic research. Our biological materials are obtained through collaborations with hospitals, pathologists and other physician specialists.Bio-options has a large repository of human tissue samples, along with serum and plasma of the major diseases, with a focus on the common tumors of the bre...
Diamics mission is to work in partnership with both individual and institutional experts to develop and market cost-effective molecular-based cancer screening and diagnostic systems that will increase long-term survival rates through early detection. Cancers that can be detected earlier by screening account for at least half of all new cancer cases.1 In addition to cervical cancer, these cancers...
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. The company is also developing this technology for the treatment of certain other types of tumors. ED...
Brachytherapy is an advanced cancer treatment. The word "brachy" is Greek for "close by" and refers to placing radioactive seeds or sources directly in the tumor. This procedure gives physicians and patients the important advantage of applying a higher dose of radiation directly to the tumor while sparing healthy tissue and surrounding organs. Brachytherapy is a localized, precise, radiation treat...
GeneSegues is a biopharmaceutical company built upon advanced, targeted drug delivery technology. We conduct research and early-stage development of proprietary oncology biopharmaceuticals using our ligand-directed, nanoencapsulation technology. Our two initial product candidates are antisense therapeutics for treatment of advanced head neck and prostate cancers. We are currently conducting animal...
Cancer is the leading cause of pre-mature death in Canada, being responsible for almost 1/3 of all potential years of life lost. During their life-time, 2 in 19 women are expected to develop breast cancer, 1 in 18 will develop colorectal cancer, and 1 in 20 will develop lung cancer. Among men, 1 in 9 will develop prostate cancer during their life-time (National Cancer Institute of Canada, 2000).
Intuitive Surgical, Inc. (Nasdaq: ISRG) is the global technology leader in robotic-assisted minimally invasive surgery (MIS). The Company's da Vinci® Surgical System offers surgeons superior visualization, enhanced dexterity, greater precision and ergonomic comfort for the optimal performance of MIS. The da Vinci System enables surgeons to perform even complex procedures such as open-heart surger...
Anova Cancer Care serves Denver and the Rocky Mountain region with the worldâs only robotic radiosurgery system designed to treat tumors anywhere in the body. Used by the nationâs leading hospitals and medical centers, the CyberKnife® System uses continual image guidance technology and computer controlled robotic mobility to track, detect and correct...
Theragenics Corporation is a leader in the production and sales of implantable radiation devices ("seeds") used in thetreatment of cancer. The Company produces and sells TheraSeed(R), which is a U.S. Food and Drug Administration (FDA) licensed device, based on the radioactive isotope palladium 103 (Pd-103). The Company received FDA clearanceto market TheraSeed(R) in 1986 and...
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography...
The Prostate Cancer Foundation (PCF) is the worldâs largest philanthropic source of support for accelerating the worldâs most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $400 million and provided funding to more than 1,500 researchers at nearly 200 institutions wor...
The Georgia Prostate Cancer Pledge Committee
